Possible factor for nonlinear pharmacokinetics of TAK-603, a new antirheumatic agent, in rats

Yoshihiko Tagawa, Kiyoshi Miwa, Kenji Yamashita, Ryoichi Tsukuda, Yoshinobu Yoshimura, Shigeharu Tanayama, Yusuke Tanigawara

Research output: Contribution to journalArticle

4 Citations (Scopus)

Abstract

A new antirheumatic, TAK-603, shows nonlinear pharmacokinetics in both animals and humans. To elucidate the mechanism of these nonlinear pharmacokinetics, in vivo and in vitro metabolism of 14C-labeled TAK-603 ([14C]TAK-603) was studied using rats as these resemble humans in their metabolic profiles. After intravenous injection of [14C]TAK-603 to rats at doses of 1, 5, and 15 mg kg-1, the total body clearance of unchanged drug decreased significantly with increasing dose, whereas the apparent distribution volume did not alter remarkably. Thus, saturation in the elimination processes was considered to be a factor responsible for the nonlinear pharmacokinetics. The disappearance of unchanged drug from the circulation, however, followed a dose-dependent first-order process, indicating that the nonlinearity observed was not merely due to saturation of the elimination capacity. In vitro studies using rat liver microsomes showed that TAK-603 competitively inhibited CYP-catalysed nifedipine oxidation and also that the demethylated metabolite M-I, the major metabolite in rats and humans, competitively inhibited the oxidation of nifedipine. These results suggested that inhibition by M-I of the metabolism of the parent drug (i.e. product-inhibition) may be the most likely factor responsible for the nonlinear pharmacokinetics of TAK-603.

Original languageEnglish
Pages (from-to)11-18
Number of pages8
JournalBiopharmaceutics and Drug Disposition
Volume20
Issue number1
DOIs
Publication statusPublished - 1999
Externally publishedYes

Fingerprint

Antirheumatic Agents
Pharmacokinetics
Nifedipine
Pharmaceutical Preparations
Metabolome
Liver Microsomes
Intravenous Injections
TAK 603

Keywords

  • Nonlinear pharmacokinetics
  • Product-inhibition
  • Rat
  • TAK-603

ASJC Scopus subject areas

  • Pharmacology (medical)
  • Pharmacology, Toxicology and Pharmaceutics(all)

Cite this

Possible factor for nonlinear pharmacokinetics of TAK-603, a new antirheumatic agent, in rats. / Tagawa, Yoshihiko; Miwa, Kiyoshi; Yamashita, Kenji; Tsukuda, Ryoichi; Yoshimura, Yoshinobu; Tanayama, Shigeharu; Tanigawara, Yusuke.

In: Biopharmaceutics and Drug Disposition, Vol. 20, No. 1, 1999, p. 11-18.

Research output: Contribution to journalArticle

Tagawa, Yoshihiko ; Miwa, Kiyoshi ; Yamashita, Kenji ; Tsukuda, Ryoichi ; Yoshimura, Yoshinobu ; Tanayama, Shigeharu ; Tanigawara, Yusuke. / Possible factor for nonlinear pharmacokinetics of TAK-603, a new antirheumatic agent, in rats. In: Biopharmaceutics and Drug Disposition. 1999 ; Vol. 20, No. 1. pp. 11-18.
@article{94224bc0b5a44590ade62375daddbc3c,
title = "Possible factor for nonlinear pharmacokinetics of TAK-603, a new antirheumatic agent, in rats",
abstract = "A new antirheumatic, TAK-603, shows nonlinear pharmacokinetics in both animals and humans. To elucidate the mechanism of these nonlinear pharmacokinetics, in vivo and in vitro metabolism of 14C-labeled TAK-603 ([14C]TAK-603) was studied using rats as these resemble humans in their metabolic profiles. After intravenous injection of [14C]TAK-603 to rats at doses of 1, 5, and 15 mg kg-1, the total body clearance of unchanged drug decreased significantly with increasing dose, whereas the apparent distribution volume did not alter remarkably. Thus, saturation in the elimination processes was considered to be a factor responsible for the nonlinear pharmacokinetics. The disappearance of unchanged drug from the circulation, however, followed a dose-dependent first-order process, indicating that the nonlinearity observed was not merely due to saturation of the elimination capacity. In vitro studies using rat liver microsomes showed that TAK-603 competitively inhibited CYP-catalysed nifedipine oxidation and also that the demethylated metabolite M-I, the major metabolite in rats and humans, competitively inhibited the oxidation of nifedipine. These results suggested that inhibition by M-I of the metabolism of the parent drug (i.e. product-inhibition) may be the most likely factor responsible for the nonlinear pharmacokinetics of TAK-603.",
keywords = "Nonlinear pharmacokinetics, Product-inhibition, Rat, TAK-603",
author = "Yoshihiko Tagawa and Kiyoshi Miwa and Kenji Yamashita and Ryoichi Tsukuda and Yoshinobu Yoshimura and Shigeharu Tanayama and Yusuke Tanigawara",
year = "1999",
doi = "10.1002/(SICI)1099-081X(199901)20:1<11::AID-BDD147>3.0.CO;2-#",
language = "English",
volume = "20",
pages = "11--18",
journal = "Biopharmaceutics and Drug Disposition",
issn = "0142-2782",
publisher = "John Wiley and Sons Ltd",
number = "1",

}

TY - JOUR

T1 - Possible factor for nonlinear pharmacokinetics of TAK-603, a new antirheumatic agent, in rats

AU - Tagawa, Yoshihiko

AU - Miwa, Kiyoshi

AU - Yamashita, Kenji

AU - Tsukuda, Ryoichi

AU - Yoshimura, Yoshinobu

AU - Tanayama, Shigeharu

AU - Tanigawara, Yusuke

PY - 1999

Y1 - 1999

N2 - A new antirheumatic, TAK-603, shows nonlinear pharmacokinetics in both animals and humans. To elucidate the mechanism of these nonlinear pharmacokinetics, in vivo and in vitro metabolism of 14C-labeled TAK-603 ([14C]TAK-603) was studied using rats as these resemble humans in their metabolic profiles. After intravenous injection of [14C]TAK-603 to rats at doses of 1, 5, and 15 mg kg-1, the total body clearance of unchanged drug decreased significantly with increasing dose, whereas the apparent distribution volume did not alter remarkably. Thus, saturation in the elimination processes was considered to be a factor responsible for the nonlinear pharmacokinetics. The disappearance of unchanged drug from the circulation, however, followed a dose-dependent first-order process, indicating that the nonlinearity observed was not merely due to saturation of the elimination capacity. In vitro studies using rat liver microsomes showed that TAK-603 competitively inhibited CYP-catalysed nifedipine oxidation and also that the demethylated metabolite M-I, the major metabolite in rats and humans, competitively inhibited the oxidation of nifedipine. These results suggested that inhibition by M-I of the metabolism of the parent drug (i.e. product-inhibition) may be the most likely factor responsible for the nonlinear pharmacokinetics of TAK-603.

AB - A new antirheumatic, TAK-603, shows nonlinear pharmacokinetics in both animals and humans. To elucidate the mechanism of these nonlinear pharmacokinetics, in vivo and in vitro metabolism of 14C-labeled TAK-603 ([14C]TAK-603) was studied using rats as these resemble humans in their metabolic profiles. After intravenous injection of [14C]TAK-603 to rats at doses of 1, 5, and 15 mg kg-1, the total body clearance of unchanged drug decreased significantly with increasing dose, whereas the apparent distribution volume did not alter remarkably. Thus, saturation in the elimination processes was considered to be a factor responsible for the nonlinear pharmacokinetics. The disappearance of unchanged drug from the circulation, however, followed a dose-dependent first-order process, indicating that the nonlinearity observed was not merely due to saturation of the elimination capacity. In vitro studies using rat liver microsomes showed that TAK-603 competitively inhibited CYP-catalysed nifedipine oxidation and also that the demethylated metabolite M-I, the major metabolite in rats and humans, competitively inhibited the oxidation of nifedipine. These results suggested that inhibition by M-I of the metabolism of the parent drug (i.e. product-inhibition) may be the most likely factor responsible for the nonlinear pharmacokinetics of TAK-603.

KW - Nonlinear pharmacokinetics

KW - Product-inhibition

KW - Rat

KW - TAK-603

UR - http://www.scopus.com/inward/record.url?scp=0032954831&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0032954831&partnerID=8YFLogxK

U2 - 10.1002/(SICI)1099-081X(199901)20:1<11::AID-BDD147>3.0.CO;2-#

DO - 10.1002/(SICI)1099-081X(199901)20:1<11::AID-BDD147>3.0.CO;2-#

M3 - Article

VL - 20

SP - 11

EP - 18

JO - Biopharmaceutics and Drug Disposition

JF - Biopharmaceutics and Drug Disposition

SN - 0142-2782

IS - 1

ER -